GAMMA Investing LLC Purchases 352 Shares of Encompass Health Co. (NYSE:EHC)

GAMMA Investing LLC grew its holdings in shares of Encompass Health Co. (NYSE:EHC) by 22.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,947 shares of the company’s stock after buying an additional 352 shares during the quarter. GAMMA Investing LLC’s holdings in Encompass Health were worth $180,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of EHC. CIBC Asset Management Inc grew its position in Encompass Health by 3.5% in the 3rd quarter. CIBC Asset Management Inc now owns 2,957 shares of the company’s stock valued at $286,000 after acquiring an additional 100 shares during the last quarter. Commonwealth Equity Services LLC increased its stake in Encompass Health by 1.3% in the 2nd quarter. Commonwealth Equity Services LLC now owns 9,845 shares of the company’s stock worth $845,000 after buying an additional 123 shares during the period. V Square Quantitative Management LLC lifted its holdings in Encompass Health by 53.0% during the 3rd quarter. V Square Quantitative Management LLC now owns 404 shares of the company’s stock valued at $39,000 after buying an additional 140 shares in the last quarter. Verdence Capital Advisors LLC boosted its position in Encompass Health by 4.6% in the 3rd quarter. Verdence Capital Advisors LLC now owns 3,670 shares of the company’s stock valued at $355,000 after buying an additional 160 shares during the period. Finally, Mount Yale Investment Advisors LLC grew its stake in Encompass Health by 6.6% in the 2nd quarter. Mount Yale Investment Advisors LLC now owns 2,749 shares of the company’s stock worth $236,000 after acquiring an additional 170 shares in the last quarter. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

Encompass Health Stock Up 1.3 %

EHC stock opened at $92.78 on Thursday. The stock has a market capitalization of $9.35 billion, a PE ratio of 22.41, a price-to-earnings-growth ratio of 1.30 and a beta of 0.89. Encompass Health Co. has a 52 week low of $67.43 and a 52 week high of $104.55. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. The firm has a 50 day moving average of $98.52 and a 200 day moving average of $93.62.

Encompass Health (NYSE:EHC) last posted its quarterly earnings data on Monday, October 28th. The company reported $1.03 EPS for the quarter, topping the consensus estimate of $0.94 by $0.09. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.33 billion. Encompass Health had a net margin of 8.10% and a return on equity of 17.60%. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.86 earnings per share. Sell-side analysts forecast that Encompass Health Co. will post 4.29 earnings per share for the current year.

Encompass Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Thursday, January 2nd will be issued a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.73%. The ex-dividend date is Thursday, January 2nd. Encompass Health’s dividend payout ratio (DPR) is 16.43%.

Wall Street Analyst Weigh In

Several research firms recently weighed in on EHC. KeyCorp lifted their price objective on Encompass Health from $115.00 to $117.00 and gave the company an “overweight” rating in a report on Tuesday, October 29th. Royal Bank of Canada boosted their price objective on shares of Encompass Health from $105.00 to $110.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. UBS Group increased their target price on Encompass Health from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Barclays boosted their price target on Encompass Health from $109.00 to $116.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 29th. Finally, Truist Financial reaffirmed a “buy” rating and set a $116.00 price objective (up previously from $108.00) on shares of Encompass Health in a research report on Wednesday, October 30th. Nine equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Encompass Health presently has an average rating of “Buy” and an average target price of $107.11.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.